-
Abhishek fireworks, Malinga spell sink Chennai
-
Napoli's Serie A title defence nears end with Lazio defeat
-
England run in 12 tries to hammer Scotland in Six Nations
-
Rybakina powers past Andreeva to reach Stuttgart final
-
At least 5 killed after gunman opens fire in Ukrainian capital
-
Bayern on cusp of title as Dortmund lose, Eta beaten on debut
-
Rublev, Fils fightbacks set up Barcelona Open final
-
Leeds pull clear of trouble, Bournemouth sink Newcastle
-
Spain rout Ukraine to boost Women's World Cup qualifying hopes
-
Bayern close in on Bundesliga title as Dortmund lose
-
Iran closes Hormuz Strait again, as Trump warns against 'blackmail'
-
US extends sanctions waiver on purchases of Russian oil
-
Trump signs order to fast-track research on psychedelic drugs
-
Cobolli downs Zverev to set up Munich final with Shelton
-
Pope arrives in Angola on Africa tour overshadowed by Trump
-
Thousands protest in Germany urging faster green shift
-
La Rochelle thump threadbare Bordeaux-Begles
-
Muchova battles past Svitolina to book Stuttgart final berth
-
Allegri rules out taking Italy job, wants to stay at AC Milan
-
Miller bludgeons Delhi to IPL win over Bengaluru
-
Pope says he regrets his remarks interpreted as a debate with Trump
-
Brentford blow chance for top six in Fulham stalemate
-
Trade ships hit in Hormuz as Iran reopening falters
-
France blames Hezbollah for French peacekeeper's death in Lebanon
-
Venezuela's Machado doesn't regret gifting Nobel Peace Prize to Trump
-
No date set for next round of Iran-US talks: Iran deputy FM
-
Iran closes Hormuz Strait again over US blockade, ships reverse course
-
'We've already beaten other favorites', Lyon's Endrick warns PSG
-
Turkey says Israel using security as a pretext to acquire 'more land'
-
Iran closes Hormuz Strait again over US blockade with ships mid-transit
-
French film star Nathalie Baye dead at 77: family to AFP
-
China sex toy makers cautiously embrace AI wave
-
Paramount's CinemaCon charm offensive gets lukewarm reception
-
Game over: Players press EU to ban 'destroying' video titles
-
Churches to the rescue of Cuba's legions of poor
-
In Trump era, fearful left-leaning Americans turn to guns
-
Pope brings Africa tour to Angola as Trump feud drags on
-
Fitzpatrick charges to one-shot lead at RBC Heritage
-
Andreeva sinks Swiatek to meet top seed Rybakina in Stuttgart semis
-
Carrick won't rule out Rashford return to Man Utd
-
Lampard restores reputation by leading Coventry to Premier League
-
'Gouged': World Cup fans to pay 'insane' $150 for NY stadium train ticket
-
Lens leave it late to edge Toulouse and keep pressure on PSG
-
Inter swat aside Cagliari to continue Serie A title procession
-
'Gouged': World Cup fans to pay $150 for NY stadium train ticket
-
Thunder stay in the moment as NBA title repeat beckons
-
US Catholics unsettled by Trump's feud with pope
-
US Supreme Court sides with Chevron in environmental case
-
World Cup fans to pay $150 for NY stadium train ticket: official
-
Gujarat's Gill consigns Kolkata to fifth defeat in IPL
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
J.Bergmann--BTB